Supplementary material: Wei et al. Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials. JAAD 2023

Published: 4 August 2023| Version 1 | DOI: 10.17632/dw5fk5y4j9.1
Contributors:
Xiaoling Wei, Anna Passera, Elisa Muscianisi , Lorenz Uhlmann , Li Chen, Santiago G. Moreno , Ruvie Martin, Marc Vandemeulebroecke , Deborah Keefe, Shoba Ravichandran, Magdalena Wozniak

Description

Supplemental text and table for: Wei et al. Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials. JAAD 2023

Files

Institutions

Novartis Pharma AG

Categories

Dermatology

Funding

Novartis

Licence